Pathology and new insights in thyroid neoplasms in the 2022 WHO classification

被引:9
|
作者
Lebrun, Laetitia [1 ]
Salmon, Isabelle [1 ,2 ,3 ]
机构
[1] Univ Libre Bruxelles ULB, Erasme Univ Hosp, Hop Univ Bruxelles HUB, CUB Hop Erasme,Dept Pathol, Brussels, Belgium
[2] ULB, Ctr Microscopy & Mol Imaging CMMI, DIAPath, Gosselies, Belgium
[3] Univ Libre Bruxelles ULB, Erasme Univ Hosp HUB, Dept Pathol, Rue Meylemeersch 90, B-1070 Brussels, Belgium
关键词
Bethesda system; fine needle aspiration; molecular testing; screening; thyroid cancer; WHO classification; TERT PROMOTER MUTATIONS; ENCAPSULATED FOLLICULAR VARIANT; INTEROBSERVER VARIABILITY; ASSOCIATION GUIDELINES; GENETIC ALTERATIONS; VASCULAR INVASION; TASK-FORCE; CARCINOMA; CANCER; NODULES;
D O I
10.1097/CCO.0000000000001012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewThe assessment of thyroid nodules is a common clinical problem, linked to the high incidence of thyroid nodules in the population and the low incidence of aggressive thyroid carcinoma. The screening is therefore one of the strengths of our patient care. Recently, the 2023 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and 2022 WHO classification of thyroid neoplasms have been released based on the definition of new entities and the growing impact of molecular testing. The aim of this review is to analyze how these upgrades can help us in the daily routine practice diagnosis of thyroid cancer.Recent findingsOur review is focused on the most frequent thyroid tumors derived from thyroid follicular cell. Fine needle aspiration (FNA) is the gold standard for the screening of thyroid nodules with very high levels of sensitivity and specificity. These sensitivity and specificity are improved by molecular testing, which refines the risk of malignancy. The 2023 TBSRTC integrates molecular data and the upgrades integrated in the 2022 WHO classification such as the 'low-risk neoplasms' and the 'high-grade follicular-cells derived carcinoma'. The morphological examination remains crucial since the capsular and/or vascular invasion are key features of malignancy in the follicular thyroid neoplasms. Low-risk neoplasms represent a clinical challenge since no specific guidelines are available. Challenges remain regarding oncocytic thyroid lesions, which are not associated with specific diagnostic molecular biomarkers. Molecular testing can help not only in deciphering the prognosis but also in the targeted therapeutic strategy.SummaryWhile molecular testing has succeeded to substantially improve the pre and postoperative diagnosis and risk stratification of thyroid tumors, the morphological examination is still central in the daily routine diagnosis of thyroid pathology. Future is the integrated diagnosis of clinical, morphological, molecular and epigenetic features with the help of artificial intelligence algorithms.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 50 条
  • [21] New 2022 WHO classification of testicular tumours
    Fichtner, Alexander
    Stroebel, Philipp
    Bremmer, Felix
    PATHOLOGIE, 2022, 43 (06): : 416 - 424
  • [22] Commentary on the 2022 WHO Classification of Haematolymphoid Tumours: Myeloid and histiocytic/dendritic neoplasms
    Robert Peter Gale
    Christophe Badie
    Leukemia, 2025, 39 (4) : 1009 - 1010
  • [23] Special Issue On the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors: a New Primer for Endocrine Pathology Practice
    Mete, Ozgur
    ENDOCRINE PATHOLOGY, 2022, 33 (01) : 1 - 2
  • [24] Special Issue On the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors: a New Primer for Endocrine Pathology Practice
    Ozgur Mete
    Endocrine Pathology, 2022, 33 : 1 - 2
  • [25] Pathology and cytologic features of thyroid neoplasms
    Malloy, Kelly M.
    Cunnane, Mary F.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 17 (01) : 57 - +
  • [26] Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification
    Stegenga, Merel T.
    Oudijk, Lindsey
    van Velsen, Evert F. S.
    Peeters, Robin P.
    Medici, Marco
    Verburg, Frederik A.
    van Ginhoven, Tessa M.
    van Kemenade, Folkert J.
    Visser, W. Edward
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [27] The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading
    Juhlin, C. Christofer
    Mete, Ozgur
    Baloch, Zubair W.
    ENDOCRINE-RELATED CANCER, 2023, 30 (02)
  • [28] The Myeloproliferative Neoplasms: Insights into Molecular Pathogenesis and Changes in WHO Classification and Criteria for Diagnosis
    Anastasi, John
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (04) : 693 - +
  • [29] WHO classification of myeloid neoplasms
    Wickenhauser, C.
    PATHOLOGE, 2018, 39 : 315 - 318
  • [30] The spectrum of mesenchymal skin neoplasms reflected by the new WHO classification
    Beyeler, M
    Kempf, W
    Hafner, J
    Burg, G
    Dummer, R
    ONKOLOGIE, 2004, 27 (04): : 401 - 406